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Induction of Lymphoidlike Stroma and
Immune Escape by Tumors That
Express the Chemokine CCL21
Jacqueline D. Shields,* Iraklis C. Kourtis,* Alice A. Tomei, Joanna M. Roberts, Melody A. Swartz†
Tumor manipulation of host immunity is important for tumor survival and invasion. Many
cancers secrete CCL21, a chemoattractant for various leukocytes and lymphoid tissue inducer
cells, which drive lymphoid neogenesis. CCL21 expression by melanoma tumors in mice
was associated with an immunotolerant microenvironment, which included the induction of
lymphoid-like reticular stromal networks, an altered cytokine milieu, and the recruitment of
regulatory leukocyte populations. In contrast, CCL21-deficient tumors induced antigen-specific
immunity. CCL21-mediated immune tolerance was dependent on host rather than tumor expression
of the CCL21 receptor, CCR7, and could protect distant, coimplanted CCL21-deficient tumors
and even nonsyngeneic allografts from rejection. We suggest that by altering the tumor
microenvironment, CCL21-secreting tumors shift the host immune response from immunogenic
to tolerogenic, which facilitates tumor progression.
Cancer fate, including progression, metas-tasis, and therapy resistance, is largelydetermined by the interactions between a
tumor and host immune cells. Immune cells can
recognize tumors by their antigenic profiles, but
many tumors manipulate these cells to escape
immune surveillance. To accomplish this, tumors
can mimic immune signaling pathways that alter
the tumor microenvironment to favor the activa-
tion of regulatory T (Treg) cells and suppress
effector functions (1–3), driving immunological
tolerance and tumor progression.
Here, we examine a mechanism of tumor-
induced immune tolerance that bears similar-
ities to the tolerance-maintaining functions of
the lymph node (LN) stroma. In the lymph
node paracortex, specialized stromal cells called
fibroblastic reticular cells (FRCs) secrete the
CCR7 ligands CCL21 and CCL19, which guide
the interactions between CCR7+ T cells and
antigen-presenting cells (APCs) needed for Tcell
education and priming. Although these events are
sufficient to trigger adaptive immunity, they are
also necessary for maintaining peripheral toler-
ance, because Treg cells require LN occupancy
and CCR7 signaling for their activation and func-
tion (4–6), and the loss of CCR7 signaling is
associated with spontaneous autoimmunity (7, 8).
The lymph node stroma itself can also promote
deletion of self-reactive cells (9, 10) and can help
to maintain homeostasis of naïve T cells (11).
We recently showed that invasive tumor cells
secrete CCL21 (12), and we verified this here in
several invasive human tumor lines cultured in
three-dimensional conditions (fig. S1A). Given
the critical role of CCR7 in both immunity and
tolerance, we asked how endogenous tumor
CCL21 expression would affect the host immune
response.
Aside from recruiting leukocytes and guiding
their interactions in the LN, CCL21 is also amain
driver of lymphoid tissue formation (13–15), as it
attracts CCR7+ lymphoid tissue inducer (LTi)
cells that drive the maturation of lymphoid
stroma (16). Notably, expression of CCL19 and
CCL21 in nonlymphoid tissues has been cor-
related with autoimmunity and inflammation, as
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Fig. 1. CCL21 expression promotes tumor
growth that is host CCR7-dependent. (A)
CCL21 protein levels (determined by ELISA)
in tumor and naïve lymph node lysates
9 days post-implantation (p.i., n ≥ 4). (B)
Day9p.i. tumor volumes.Multiple CCL21low
clones were implanted (CCL21lowi, clone
21/217; CCL21lowii, clone 21/217 D8;
CCL21lowiii, clone 21/401 H5; all n ≥ 3;
control, n = 22; CCL21high, n = 10). Bars
show medians T SE. (C) Tumor infiltration
of CD45+ leukocytes as determined by flow
cytometry, and (D to F) APC subpopula-
tions at day 9 p.i. in wild-type (n ≥ 10) and
CCR7–/–mice (n= 3); bars showmedians T
SE. (G) CCR7+ leukocyte infiltrates in
tumors 9 days p.i. in wild-type (n ≥ 4) and
CCR7–/–mice (n=3). Bars showmedians T
SE. (H) Day 9 p.i. control tumor volumes
in wild-type mice treated with CCR7 neu-
tralizing antibodies or control IgG, or in
CCR7 –/– mice (n ≥ 3). Data represent
means T SEM. (I) Volumes of single (n=22)
and co-implanted tumors (n ≥ 7) at day 9
p.i. Data represent means T SEM. *P <
0.05, **P< 0.01 relative to control tumors,
and #P < 0.05 relative to single implanted
CCL21low tumors, one-way analysis of
variance (ANOVA) and Bonferroni post-test
adjustment.
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well as immune suppression (7, 15, 17). Likewise,
exogenousCCR7 ligands have been demonstrated
to induce both antitumor immunity and tumor
immune suppression (7, 18, 19). Here, in contrast
to the studies using exogenous CCR7 ligands, we
examine the effects of endogenous melanoma
CCL21 expression on tumor fate.
We engineered three stable cell sublines de-
rived from murine B16-F10 melanomas to
knockdown endogenous CCL21 secretion by
shRNA (CCL21low), to express endogenous
amounts (scrambled shRNA control) at amounts
comparable to those measured in normal LNs, or
to overexpress CCL21 (CCL21high) (20) (Fig. 1A).
Surprisingly, when implanted into immune com-
petent syngeneic C57BL/6 mice, CCL21high and
control tumors grew significantly larger than
CCL21low tumor clones (Fig. 1B)—even though
the CCL21-expressing tumors attracted more
CD45+ leukocytes, including APCs and CCR7+
leukocytes (Fig. 1, C to G, and fig. S1, B to E).
Note that CCR7+ APCs in CCL21-expressing
tumors retained the capacity to traffic from the
tumor to the draining LNs upon uptake of 0.5
mm fluorescent beads (fig. S2), which sug-
gested that their ability to uptake antigen was
not impaired.
These differences in growth could have resulted
either from the host response to the tumor or from
autocrine effects of CCL21 signaling on tumor
cells themselves, because they express CCR7
(fig. S1F). In vitro, however, the three different
cell lines proliferated, formed spheroids, and
migrated up a gradient of exogenous CCL21
similarly (fig. S1, G to J); furthermore, these
behaviors were unaltered by the addition of ex-
ogenous CCL21 protein or with CCR7-blocking
antibodies, which indicated that the differences
seen in growth were dependent on the in vivo
environment.
Moreover, tumor growth was host CCR7-
dependent, because control tumors grew poorly
when implanted into CCR7-deficient mice or into
wild-type mice treated systemically with CCR7-
blocking antibodies (Fig. 1, C to H). Therefore,
tumor-mediated, CCL21-dependent modulation
of the host response, rather than autocrine effects
on the tumor itself, was responsible for the dif-
ferential tumor propagation observed.
To further verify that these growth differences
were due to variations in the host immune re-
sponse to the tumor, rather than to changes in-
curred on the tumor cells themselves by autocrine
CCR7 signaling, we coimplanted CCL21low and
control tumors into the same mouse, each on
opposite shoulders. In these mice, control tumors
could rescue the growth of CCL21low tumors to
control levels (Fig. 1I), which further demon-
strated that a host response was responsible for
the differences in tumor growth seen earlier.
Given this apparent contradiction—increased
tumor growth associated with enhanced leuko-
cyte attraction and normal APC trafficking to
LNs—we next asked how the secretion of
CCL21 could affect interactions between the
tumor and its immune cell infiltrates. Upon ex-
amining the Tcell populations within the tumors,
we found that, although control and CCL21high
tumors attracted more T cells overall (Fig. 2A),
CCL21low tumors contained higher densities of
T cells (Fig. 2B) and more melanoma antigen
[tyrosinase-related protein 2 (Trp2)]-specific
CD8+ T cells (Fig. 2C). This was consistent with
increased amounts of interferon-g (IFN-g), inter-
leukin 2 (IL-2), and IL-4 in CCL21low tumors
(Fig. 2D and fig. S4, A and B), cytokines that are
all associated with cytotoxic T cell responses
and antitumor immunity (1–3). In contrast, con-
trol and CCL21high tumors contained more CD4+
CD25+FoxP3+ Treg cells (Fig. 2E and fig. S3, A
to C) and higher amounts of transforming growth
Fig. 2. CCL21 expression leads to a tolerogenic tu-
mor microenvironment. (A) Total CD3e+ T cells with-
in CCL21low, control, and CCL21high (n = 9) tumors
(n ≥ 9). Bars show medians T SE. (B) Number of T
cells per unit tumor volume (n ≥ 9). Data represent
means T SEM. (C) Frequency of tyrosinase-related
protein–2 peptide SVYDFFVWL (Trp2180-188)–specific T
cells (CD19–CD3e+CD8a+SVYDFFVWL-MHC pentamer+)
(29) within tumors of wild-type and CCR7–/– mice, as
determined by flow cytometry. Bars show medians T SE.
(D) IFN-g protein levels within tumors as determined by
enzyme-linked immunosorbent assay (ELISA) (n = 8).
Data represent means T SEM. (E) Quantification of
tumor-infiltrated Treg cells within CCL21
low, control, and
CCL21high tumors (n ≥ 5). Data represent means T SEM.
(F) Total TGF-b1 protein levels within tumors as deter-
mined by ELISA (n ≥ 4). Data represent means T SEM. (G)
CD11c–CD11b+F4/80–Gr1high myeloid-derived suppressor
tumor infiltrates (n ≥ 6). Bars show medians T SE. (H)
Intratumoral T cell populations and Treg cells within
coimplanted CCL21low and control tumors (n ≥ 4). Data
represent means T SEM. (I) Comparison of tumor volumes
in wild-type (n ≥ 10) and athymic mice (Foxn1nu/nu, n =
4). Bars showmedians T SE. (J) CD11c–CD11b+F4/80–Gr1high
myeloid-derived suppressor tumor infiltrates in Foxn1nu/nu
mice (n = 4). Bars show medians T SE. All data were taken
at day 9 p.i. The symbols * or # indicate P < 0.05, and
double superscripts indicate P < 0.01 compared with
respective control tumors.
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factor–b1 (TGF-b1) (Fig. 2F). TGF-b1 is a key
regulator of tumor tolerance that suppresses
antigen-specific CD8+ T cell function, promotes
Treg cell induction, and shifts the macrophage
populations from classically activated (M1) to
alternatively activated, protumor (M2) pheno-
types (21, 22). Furthermore, tumor expression
of CCL21 led to enhanced CCR7-dependent
attraction of CD11b+CD11c–F4/80–Gr1highmyeloid-
derived suppressor cells (MDSCs) that also ex-
pressed inducible nitric oxide synthase (Fig. 2G
and fig. S4G), a cell type known to drive tumor
progression (1–3). Coincident with more MDSCs
were higher amounts of the MDSC chemo-
attractants CCL2 and C5a in CCL21-expressing
tumors (fig. S4, D and E). Finally, when im-
planted into the same mouse but on opposite
shoulders, CCL21low andCCL21high tumors (which
grew similarly large) (Fig. 1I) displayed similar
distributions of T cell populations (Fig. 2H), in-
cluding Treg cell numbers similar to those seen
in CCL21high tumors grown alone.
The central role of the adaptive immune
response in the prevention of CCL21low tumor
establishment was further demonstrated by
using athymic Foxn1nu/numice, which lack Tcells
and thus cell-mediated immunity. In these mice,
CCL21low tumors grew just as large as control and
CCL21high tumors (Fig. 2I), despite their impaired
recruitment of MDSCs (Fig. 2J).
We next examined the tumor stroma, because
peripheral expression of CCL21 can drive lymph-
oid neogenesis via recruitment of CCR7+ LTi cells
(10, 13–15, 23). In the LN paracortex, FRCs are
the major source of CCR7 ligands and are
characterized by glycoprotein gp38 and the ER-
TR7 antigen. In control and CCL21high tumors,
we observed FRC networks at the tumor margins
that were reminiscent of those in the LN para-
cortex (Fig. 3, A and B, and fig. S5). These
tumor stromal networks expressed gp38, which
in tumors has been associated with poor prog-
nosis (24). CCL21-expressing tumors, but not
CCL21low tumors, also expressed the catabolic
enzyme indoleamine 2,3-dioxygenase (IDO)
(Fig. 3C), a potent tumor immune suppressor
(25), as well as complement receptor 1–related
gene/protein y (Crry) (Fig. 3D), a complement-
regulating protein that helps maintain self-
tolerance and that can inhibit antitumor immunity
(26). Blood vessel density appeared similar in all
tumors (Fig. 3E), but some vessels in control and
CCL21high tumors also expressed peripheral node
addressin (PNAd), which is normally associ-
ated with LN high endothelial venules (HEVs)
(fig. S5C).
Consistent with these LN-like stromal changes,
CD45+CD3e–CD4+RORgt+ LTi cells were pref-
erentially recruited to control and CCL21high
tumors in a host CCR7-dependent manner,
Fig. 3. CCL21-expressing tumors develop stro-
mal zones reminiscent of lymph node paracortex
stroma. (A) Characteristic lymphoid stroma-
associated markers gp38 (red), ER-TR7 (green),
and LYVE-1 (cyan) in nondraining axillary lymph
nodes and peripheral stromal zones of CCL21low,
control, and CCL21high tumors by confocalmicros-
copy at day 21 p.i. (B) Secretion of CCL21 (green)
by gp38+ (red) ER-TR7+ (cyan) stromal cells in
lymph nodes and tumors. (C) IDO (green)
production in the gp38+ (red) tumor stroma.
(D) Expression of the complement regulating
protein Crry (red) within stromal (ER-TR7, green)
compartments of lymph nodes and tumors. (E)
Blood (CD31+, red) and lymphatic (LYVE-1+,
green) vessels in lymph nodes and tumors. In all
images, nuclei are counterstained with 4′,6′-
diamidino-2-phenylindole (DAPI), and dotted
lines denote tumor (T)–dermis (D) border. LN,
lymph node; C, capsule; P, paracortex. Scale bars,
50 mm. (F) Numbers of CD3e–CD4+RORgt+ LTi
cells detected in tumors from wild-type (n ≥ 3) or CCR7–/– mice (control tumors only, n = 4). Bars show medians T SE. (G) Volumes of control tumors day 9 p.i.
from wild-type C57/BL6 (n = 22), wild-type 129/P2 (n = 5), and LTi-deficient Rorc(gt)GFP/GFP mice (n = 4). Data represent means T SEM.
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both in wild-type mice (Fig. 3F and fig. S6A)
and Rorc(gt)+/GFP mice, which generate GFP-
expressing LTi cells (23) (fig. S6B). In contrast,
CCL21-enhanced tumor growth was absent in
LTi-deficient Rorc(gt)GFP/GFP mice (Fig. 3G).
Therefore, tumor expression of CCL21 was cor-
related with LTi-cell recruitment, although it is
not clear whether LTi-cell recruitment was re-
quired for the CCL21-enhanced tumor growth
and host immune tolerance observed.
This host tolerogenic response to CCL21-
secreting tumors could also be demonstrated with
another murine tumor cell line, islet beta tumor
cells (bTCs) (27), which, when transduced to
stably overexpress CCL21, grew significantly
larger and contained more Treg cells than control-
transduced counterparts in syngeneic C57BL/6
mice (Fig. 4, A and B). In addition, CCL21 over-
expression could even rescue nonsyngeneic
allografts, including B16-F10 melanomas im-
planted into BALB/C,129/P2 and S2mice (Fig. 4,
C and D). In these cases, we again found that,
although CCL21low tumors grew poorly, control
and CCL21high tumors grew robustly.
Taken together, these data suggest that CCL21
secretion by tumors led to a tolerogenic tumor
microenvironment with stromal features resem-
bling those of the LN paracortex. Consistent
with recent findings that LN stroma itself plays
an important role in promoting tolerance to self-
antigens (9), we hypothesize that tumor CCL21-
drivenmimicry of the LN stroma helps promote a
tolerogenic switch in the host immune response.
Several functions of CCL21 could help to
drive the regulatory shift in the T cell popula-
tions that we saw in CCL21-expressing tumors.
CCL21 can recruit naïve T cells to peripheral
sites (15, 28) and can promote their differenti-
ation into Treg cells while inducing effector T
cell senescence (7). The coincident development
of the specialized stroma in CCL21-expressing
tumors might enhance both T cell trafficking into
the tumor and their interactions with APCs or
even the stromal cells themselves (9). Such inter-
actions within the regulatory cytokine environment
of the tumor may promote Treg cell activation and
a further shift in the cytokine microenvironment
toward one that is less immunogenic.
These changes are consistent with earlier
reports that CCR7 signaling is required for the
maintenance of peripheral self-tolerance (4, 7, 8),
andwith reports demonstrating promotion of dele-
tional tolerance by the lymphoid stroma (9, 10). In
contrast, CCL21 has also been associated with
autoimmunity (7, 15), as it drives the formation
of lymphocytic infiltrates and tertiary lymphoid
structures. Such structures are characterized by B
cell follicle formation (14); however, we did not
detect B cell clusters in the tumors examined here
(fig. S4F). These conflicting reports (7) empha-
size that the timing and context in which CCR7+
leukocytes are recruited to the tumor, and the
tumor cytokine environment, can modulate the
outcome. Furthermore, it has been suggested that
CCR7 ligands in the tumor might inhibit allo-
graft rejection by entrapment of the APCs inside
the tumor, which prevents them from migrating
out tomount an immune response (19), andwhich
our data do not support (fig. S2). Instead, we
found CCL21-expressing tumors could prevent
rejection of a nonsyngeneic allograft. We propose
that, whereas CCL21-secreting tumors attract
MDSCs, Treg cells, and naïve Tcells to the tumor
microenvironment, it also induces lymphoid-like
stroma that can equip the developing tumor with a
substrate to promote the induction of Treg cells
and further guide naïve T cell interactions with
APCs, all under a regulatory cytokine milieu
(fig. S7). These findings hold therapeutic signifi-
cance, particularly to tumor vaccine strategies and
to emerging antitumor immunotherapies utiliz-
ing chemokines (including CCL21 and CCL19)
(7) to functionally bias the recruited immune cell
infiltrates within the tumor.
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Fig. 4. CCL21 promotes survival of orthotopic and nonsyngeneic tumor
allografts. (A) Growth rates for orthotopically implanted control-transfected
and CCL21-overexpressing b tumor cells (bTC-control and bTC-CCL21high; n=7).
Data represent means T SEM. (B) Intratumoral Treg cells within control b tumors.
Data represent means T SEM. (C) Volumes of CCL21low, control, and CCL21high
tumors in nonsyngeneic BALB/C recipients at days 9 and 14 p.i. (n = 4).
Data represent means T SEM. (D) Volumes of CCL21low, control, and CCL21high
tumors in nonsyngeneic 129/P2 and 129/S2 recipients 9 days p.i. (n ≥ 2).
Bars show medians T SE. *P < 0.05, **P < 0.01 compared with relevant
controls.
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